1-3 of 3
Jeroen J.W.M. Janssen, MD PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial

Markus Pfirrmann, PhD, Francois-Xavier Mahon, MD PhD, Joelle Guilhot, PhD, Johan Richter, MD, Antonio Almeida, MD PhD, Jeroen J.W.M. Janssen, MD PhD, Jiri Mayer, MD, Kimmo Porkka, MD PhD, Panayiotis Panayiotidis, MD PhD, Ulla Olsson-Stromberg, MD PhD, Marc G. Berger, MD PhD, Joana Diamond, PhD, Hans Ehrencrona, MD PhD, Veli Kairisto, Katerina Machova Polakova, Martin C. Müller, MD, Satu Mustjoki, MD PhD, Andreas Hochhaus, MD, Susanne Sauβele, MD, Henrik Hjorth-Hansen, MD PhD
Journal: Blood
Blood (2016) 128 (22): 789.
https://doi.org/10.1182/blood.V128.22.789.789
Published: 2016
Journal Articles

Indoleamine 2,3-Dioxygenase (IDO1) Levels and Activity Are Increased in Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) and Correlate with Molecular Response to Nilotinib Therapy

Sieghart Sopper, PhD, Satu Mustjoki, MD PhD, Gunther Gastl, Prof., Dr., Zlatko Trajanoski, Prof. Dr., Frank Giles, MD MB, Andreas Hochhaus, MD, Simon Geisler, Dietmar Fuchs, Prof. Dr., Dominik Wolf, MD, Jeroen J.W.M. Janssen, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1912.
https://doi.org/10.1182/blood.V128.22.1912.1912
Published: 2016
Journal Articles

CML Treatment in Dutch Hospitals with Low Patient Volumes Is Associated with a Substandard Quality of Molecular Response Monitoring

Inge G.P. Geelen, MD, Noortje Thielen, MD PhD, Jeroen J.W.M. Janssen, MD PhD, Tanja Roosma, Otto Visser, MD PhD, Jan J. Cornelissen, MD PhD, Peter E. Westerweel, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1913.
https://doi.org/10.1182/blood.V128.22.1913.1913
Published: 2016